Orion Pharma Limited Sustainability Profile
Orion Pharma Limited, a prominent player in the pharmaceutical industry, is headquartered in Bangladesh (BD) and has established a significant presence across various operational regions. Founded in 1965, the company has achieved notable milestones, including the development of a diverse portfolio of high-quality generic and branded medications. Specialising in therapeutic areas such as cardiology, diabetes, and infectious diseases, Orion Pharma is recognised for its commitment to innovation and quality. Its core products, which include a range of prescription medications and over-the-counter solutions, are distinguished by their efficacy and affordability. With a strong market position, Orion Pharma Limited has garnered accolades for its contributions to healthcare, making it a trusted name in the pharmaceutical sector. The company continues to focus on expanding its reach and enhancing its product offerings to meet the evolving needs of patients and healthcare providers.
DitchCarbon Score
How does Orion Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orion Pharma Limited's score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Orion Pharma Limited's reported carbon emissions
Orion Pharma Limited, headquartered in Bangladesh (BD), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company has not established documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As there are no emissions data or reduction initiatives available, it is unclear how Orion Pharma Limited is addressing its carbon footprint or contributing to climate action within the pharmaceutical industry. The lack of reported emissions and targets suggests a need for enhanced transparency and commitment to sustainability practices. In the context of the pharmaceutical sector, companies are increasingly expected to adopt robust climate strategies, including setting measurable targets for reducing greenhouse gas emissions across all scopes (Scope 1, 2, and 3). Without specific data or commitments, Orion Pharma Limited's position on climate action remains ambiguous.
How Carbon Intensive is Orion Pharma Limited's Industry?
How Carbon Intensive is Orion Pharma Limited's Location?
Orion Pharma Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Orion Pharma Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.